News Conference News ACC 2025 SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes Michael O'Riordan March 29, 2025
News Conference News ACC 2024 Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI Shelley Wood April 06, 2024
News Conference News ACC 2023 STREAM-2: Half-Dose Tenecteplase Safe, Effective in Older STEMI Patients L.A. McKeown March 10, 2023
News Conference News ACC 2023 Viability Testing Fails to Find HF Patients Who’d Benefit From PCI in REVIVED-BCIS2 Michael O'Riordan March 09, 2023
News Conference News ACC 2023 STOP-CA: Atorvastatin Curbs Heart Function Decline During Chemotherapy L.A. McKeown March 04, 2023
News Opinion Editor's Corner ACC 2023 What’s Going to Be Hot at ACC/WCC 2023? Shelley Wood February 27, 2023
News Conference News ACC 2022 No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3 Michael O'Riordan April 13, 2022
News Conference News ACC 2021 Complete Revascularization Analysis of ISCHEMIA Opens ‘Pandora’s Box’ Michael O'Riordan May 18, 2021
News Conference News ACC 2021 PARADISE-MI: ARNI Doesn’t Surpass ACE Inhibitor After Acute MI L.A. McKeown May 15, 2021
News Conference News ACC 2021 Occluding the LAA During Surgery Lowers Stroke Risk: LAAOS III Todd Neale May 15, 2021
News Conference News ACC 2020 Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT Todd Neale April 02, 2020
News Conference News ACC 2020 Anatomic Burden, Ischemia Severity, and Outcomes in ISCHEMIA Shelley Wood March 29, 2020
News Conference News ACC 2019 ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend Shelley Wood March 11, 2019
News Conference News ACC 2018 ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last Shelley Wood March 05, 2018
News Conference News ACC 2018 Flu Vaccine Reduces Mortality, Hospitalization in HF Patients: Meta-analysis Michael O'Riordan March 01, 2018
News Conference News ACC 2017 High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI Michael O'Riordan March 21, 2017
News Conference News ACC 2017 FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo Michael O'Riordan March 17, 2017
News Conference News ACC 2017 ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More Shelley Wood March 10, 2017
News Conference News ACC 2017 Erectile Dysfunction Meds Linked to Fewer Death and HF Hospitalizations After MI L.A. McKeown March 09, 2017